Department of Internal Medicine, College of Integrated Chinese and Western Medicine of Hunan University of Chinese Medicine, Changsha, 410208, China.
Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
Chin J Integr Med. 2022 Jul;28(7):636-643. doi: 10.1007/s11655-021-3449-8. Epub 2021 Aug 25.
To identify specific Chinese medicines (CM) that may benefit patients with primary liver cancer (PLC), and to explore the mechanism of action of these medicines.
In this retrospective, singlecenter study, prescription information from PLC patients was used in combination with Traditional Chinese Medicine Inheritance Supports System to identify the specific core drugs. A system pharmacology approach was employed to explore the mechanism of action of these medicines.
Taking CM more than 6 months was significantly associated with improved survival outcomes. In total, 77 putative targets and 116 bioactive ingredients of the core drugs were identified and included in the analysis (P<0.05). A total of 1,036 gene ontology terms were found to be enriched in PLC. A total of 75 pathways identified from Kyoto Encyclopedia of Genes and Genomes were also enriched in this disease, including fluid shear stress, interleukin-17 signaling, signaling between advanced glycan end products and their receptors, cellular senescence, tumor necrosis factor signaling, p53 signaling, cell cycle signaling, steroid hormone biosynthesis, T-helper 17 cell differentiation, and metabolism of xenobiotics by cytochrome. Docking studies suggested that the ingredients in the core drugs exert therapeutic effects in PLC by modulating c-Jun and interleukin-6.
Receiving CM for 6 months or more improves survival for the patients with PLC. The core drugs that really benefit for PLC patients likely regulates the tumor microenvironment and tumor itself.
鉴定可能有益于原发性肝癌（PLC）患者的特定中药（CM），并探讨这些药物的作用机制。
本回顾性单中心研究采用 PLC 患者的处方信息，结合中医传承支持系统，鉴定特定核心药物。采用系统药理学方法探讨这些药物的作用机制。
服用 CM 超过 6 个月与生存结局的改善显著相关。共鉴定出 77 个假定靶点和 116 种核心药物的生物活性成分，并纳入分析（P<0.05）。PLC 中发现了 1036 个基因本体术语的富集。从京都基因与基因组百科全书鉴定的 75 条通路也在该疾病中富集，包括流体剪切应激、白细胞介素-17 信号、晚期糖基末端产物与其受体之间的信号、细胞衰老、肿瘤坏死因子信号、p53 信号、细胞周期信号、类固醇激素生物合成、T 辅助 17 细胞分化和细胞色素介导的外源化合物代谢。对接研究表明，核心药物中的成分通过调节 c-Jun 和白细胞介素-6 在 PLC 中发挥治疗作用。
接受 CM 治疗 6 个月或更长时间可改善 PLC 患者的生存。真正有益于 PLC 患者的核心药物可能调节肿瘤微环境和肿瘤本身。
